*2.6. Production*

The strain *Embleya* sp. NEAU-wh3-1 was grown on the ISP medium 2 (yeast extract-malt extract agar) and incubated for 6–7 days at 28 ◦C. The spores of the strain were transferred into two 1.0 L Erlenmeyer flasks containing 250 mL of the seed medium and incubated at 28 ◦C for 48 h on a rotary shaker at 250 r.p.m. All of the media were sterilized at 121 ◦C for 30 min. The seed culture (8%) was transferred into 60 flasks (1.0 L) containing 250 mL of production broth. The production broth was composed of maltodextrin 4%, lactose 4%, yeast extract 0.5%, MOPS 2%, at pH 7.2–7.4. The flasks were incubated at 28 ◦C for 7 days, shaken at 250 r.p.m.

### *2.7. Extraction and Isolation*

The final 15.0 L production broth was filtered to separate supernatant and mycelial cake. The supernatant was subjected to a Diaion HP-20 resin column and eluted with 95% EtOH. The mycelial cake was washed with water (3 L) and subsequently extracted with MeOH (3 L) to obtain soluble material. The MeOH extract and the EtOH eluents were evaporated under reduced pressure at 50 ◦C to yield the crude extract (24 g). The crude extract was chromatographed on a silica gel column and eluted with a stepwise gradient of CH2Cl2/MeOH (95:5/90:10/85:15/80:20/70:30/65:35, *v*/*v*) and giving three fractions (Fr.1–Fr.3) based on the TLC profiles, which was performed on silica-gel plates with solvent system of CHCl3/MeOH (9:1, *v*/*v*). The Fr.1 was subjected to a Sephadex LH-20 column eluted with CH2Cl2/MeOH (1:1, *v*/*v*) and detected by TLC to give two subfractions (Fr.1-1-Fr.1-2). The Fr.1-1 was further isolated by semi-preparative HPLC (Agilent 1100, Zorbax SB-C18, 5 μm, 250 × 9.4 mm inner diameter; 1.5 mL min<sup>−</sup>1; 254 nm; Agilent, PaloAlto, CA, USA) eluting with CH3CN/H2O (90:10, *v*/*v*) to give compound **1** (tR 25.06 min, 10.5 mg), the Fr.1-2 was further isolated by preparative HPLC (Shimadzu LC-8 A, Shimadzu-C18, 5 <sup>μ</sup>m, 250 <sup>×</sup> 20 mm inner diameter; 20 mL min−1; 220 /254 nm; Shimadzu, Kyoto, Japan) eluting with a stepwise gradient MeOH/H2O (30–80%, *v*/*v* 30 min), and giving compound **2** (tR 12.7 min, 7.5 mg), compound **3** (tR 17.5 min, 12.7 mg) and compound **4** (tR 22.6 min, 16.3 mg). The Fr.2 was subjected to another silica gel column eluted with n-hexane/acetone (95:5-60:40, *v*/*v*) and further purified by semi-preparative HPLC (Agilent 1100, Zorbax SB-C18, 5 μm, 250 × 9.4 mm inner diameter; 1.5 mLmin−1; 254 nm; Agilent, PaloAlto, CA, USA) eluting with CH3CN/H2O (75:25, *v*/*v*) to give compound **5** (tR 15.1 min, 13.5 mg) and compound **6** (tR 24.3 min, 18.5 mg). Fr.3 was treated by an another silica gel column and eluted with a stepwise gradient of n-hexane/acetone (100:0-40:60, *v*/*v*) to give three fractions Fr.3-1–Fr.3-3 according to their TLC profiles, which was observed on silica-gel plates with solvent system of n-hexane/acetone (1:3, *v*/*v*). The Fr.3-3 was further purified by semi-preparative HPLC (Agilent 1260, Zorbax SB-C18, 5 μm, 250 × 9.4 mm inner diameter; 1.5 mL min−1; 220nm; 254 nm; Agilent, PaloAlto, CA, USA) eluting with CH3CN/H2O (45:55, *v*/*v*) to obtain compounds **7** (tR 25.1 min, 13.0 mg) and **8** (tR 30.1 min, 7.5 mg).
